Novogen (KZIA) Competitors $8.27 -0.06 (-0.72%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$8.20 -0.07 (-0.85%) As of 08/14/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KZIA vs. SCYX, RANI, KPTI, ITRM, AKTX, ALXO, BTAI, CLSD, EQ, and CLNNShould you be buying Novogen stock or one of its competitors? The main competitors of Novogen include SCYNEXIS (SCYX), Rani Therapeutics (RANI), Karyopharm Therapeutics (KPTI), Iterum Therapeutics (ITRM), Akari Therapeutics (AKTX), ALX Oncology (ALXO), BioXcel Therapeutics (BTAI), Clearside Biomedical (CLSD), Equillium (EQ), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry. Novogen vs. Its Competitors SCYNEXIS Rani Therapeutics Karyopharm Therapeutics Iterum Therapeutics Akari Therapeutics ALX Oncology BioXcel Therapeutics Clearside Biomedical Equillium Clene SCYNEXIS (NASDAQ:SCYX) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment. Do analysts prefer SCYX or KZIA? Novogen has a consensus target price of $14.00, indicating a potential upside of 69.29%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Novogen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more risk & volatility, SCYX or KZIA? SCYNEXIS has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, Novogen has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500. Does the media favor SCYX or KZIA? In the previous week, SCYNEXIS had 6 more articles in the media than Novogen. MarketBeat recorded 8 mentions for SCYNEXIS and 2 mentions for Novogen. Novogen's average media sentiment score of 1.43 beat SCYNEXIS's score of 0.73 indicating that Novogen is being referred to more favorably in the news media. Company Overall Sentiment SCYNEXIS Positive Novogen Positive Which has preferable valuation & earnings, SCYX or KZIA? Novogen has lower revenue, but higher earnings than SCYNEXIS. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSCYNEXIS$2.63M11.89-$21.29M-$0.40-2.00Novogen$1.51M5.53-$17.56MN/AN/A Do institutionals and insiders hold more shares of SCYX or KZIA? 54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is SCYX or KZIA more profitable? Novogen has a net margin of 0.00% compared to SCYNEXIS's net margin of -599.05%. Novogen's return on equity of 0.00% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets SCYNEXIS-599.05% -41.02% -26.14% Novogen N/A N/A N/A SummaryNovogen beats SCYNEXIS on 10 of the 15 factors compared between the two stocks. Get Novogen News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricNovogenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.39M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2825.74Price / Sales5.53356.37460.47115.79Price / CashN/A43.0338.2159.48Price / Book-0.848.608.856.15Net Income-$17.56M-$54.65M$3.25B$265.06M7 Day Performance1.85%5.86%3.72%2.60%1 Month Performance-23.43%8.86%5.86%2.83%1 Year Performance-57.04%13.33%30.34%25.58% Novogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIANovogen3.9894 of 5 stars$8.27-0.7%$14.00+69.3%-53.7%$8.39M$1.51M0.0012Positive NewsShort Interest ↓Gap DownSCYXSCYNEXIS1.5776 of 5 stars$0.86-2.2%N/A-51.4%$33.60M$3.75M-1.5460News CoverageEarnings ReportGap UpRANIRani Therapeutics3.4968 of 5 stars$0.52+4.0%$7.33+1,310.3%-79.1%$32.87M$1.03M-0.57110Short Interest ↓KPTIKaryopharm Therapeutics3.6495 of 5 stars$3.80+0.8%$37.40+884.2%-61.6%$32.83M$145.24M-0.29380Earnings ReportAnalyst ForecastAnalyst RevisionITRMIterum Therapeutics2.438 of 5 stars$0.74+2.9%$9.00+1,124.5%-32.2%$32.83MN/A-0.8610Gap UpAKTXAkari Therapeutics3.0984 of 5 stars$1.01-3.5%$5.00+393.6%-69.5%$32.60MN/A0.009Upcoming EarningsALXOALX Oncology2.9092 of 5 stars$0.61-0.7%$3.30+441.0%-74.6%$32.57MN/A-0.2540Earnings ReportBTAIBioXcel Therapeutics4.4611 of 5 stars$5.32-16.9%$49.25+825.8%-56.3%$32.24M$2.27M-0.3990Earnings ReportShort Interest ↓Gap DownCLSDClearside Biomedical2.8119 of 5 stars$0.41+0.5%$4.20+937.0%-56.0%$31.80M$1.66M-1.0930Earnings ReportShort Interest ↑Gap UpEQEquillium3.0484 of 5 stars$0.88-0.8%$3.00+241.3%+22.7%$31.40M$41.10M-2.2540Earnings ReportShort Interest ↓Gap UpCLNNClene3.2213 of 5 stars$3.75-1.8%$40.00+966.7%-27.4%$31.01M$340K-0.93100News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastGap Down Related Companies and Tools Related Companies SCYX Alternatives RANI Alternatives KPTI Alternatives ITRM Alternatives AKTX Alternatives ALXO Alternatives BTAI Alternatives CLSD Alternatives EQ Alternatives CLNN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZIA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novogen Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Novogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access